ABT Abbott Laboratories
Company Analysis
Latest News
🟢 Abbott is trading 4.72% up today as broader markets rally
Abbott is trading 4.72% up at $114.56, alongside a strong broader-market rally on November 4, 2026. - The S&P 500 rose 1.72%, the Nasdaq 2.16%, and the Dow...
Abbott Wins FDA Approval for Device Treating Heart-Valve Replacement Leaks
Abbott Laboratories said the U.S. Food and Drug Administration (FDA) approved a new device to treat leaks that can occur after heart valve replacement. The...
Abbott Announces Plan to Spin Off its $8.5 Billion Global Nutrition Business
Abbott Laboratories announced its intention to separate its global nutrition business into an independent, publicly traded company. The transaction is planned...
Abbott Cuts Itself in Half and Trims Its Outlook — Can a Leaner Company Command a Higher Price?
Shares dropped 4.3% to $98.00 after Abbott Laboratories announced it will spin off its Nutrition business into a standalone public company by late 2027 — while...
🔴 Abbott is trading 4.3% down in pre-market after announcing Nutrition spin-off plans
Abbott is trading at $98.00, 4.3% down in pre-market after announcing plans to separate its Nutrition business into a publicly traded company by the end of...
Abbott Secures EU CE Mark for Cologuard Plus Screening Test
Abbott Laboratories said its Cologuard Plus test received a CE Mark under the European Union’s regulations for in vitro diagnostic devices. The certification...
Abbott Laboratories Q3 2026 Earnings Preview: What Analysts Expect on October 21, 2026
Abbott Laboratories is projected to report Q3 2026 revenue of $11.21 billion and adjusted EPS of $1.42, with shares currently trading at $128.45 against an...
Abbott's FDA Win on Heart Failure Monitoring Lifts Shares 6% — But Can a Smartphone App Really Move the Needle for a $170 Billion Company?
Shares of Abbott Laboratories surged 6.3% to $106.48 after the company disclosed that the FDA approved major new capabilities for its implantable heart-failure...
🟢 Abbott is trading 6.3% up in after-hours trading amid FDA approval of new CardioMEMS capabilities
Abbott is trading at $106.48, up 6.34% in after-hours trading, with FDA approval of new CardioMEMS capabilities a possible catalyst. - On October 5, Abbott...
Abbott Laboratories targets rise, led by FreeStyle Libre and cancer screening
Wall Street analysts are raising price targets for Abbott Laboratories following strong second-quarter 2026 financial results. The company reported a 13%...
🟢 Abbott is trading 5.7% up in after-hours trading with no verified catalyst explaining the move
Abbott is trading at $108.43, up 5.73%, with no verified company-specific announcement or late-breaking catalyst explaining the after-hours move. - The stock...
🟢 Abbott is trading 13.72% up in after-hours trading despite no identified company-specific catalyst
Abbott is trading 13.72% up at $116.28 after-hours amid a broad risk-on backdrop; available coverage identifies no company-specific catalyst for the unusually...
Abbott Stock Gains, Settles DOJ Baby Formula Case for $385 Million
Abbott Laboratories shares rose Monday, ending a six-day losing streak. The company reached a $385 million settlement with the U.S. Department of Justice. The...
Abbott wins FDA approval for dual-energy catheter to treat irregular heartbeats
Abbott received U.S. Food and Drug Administration (FDA) approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled. The device treats atrial fibrillation...
Mason Hawkins' Southeastern AM Reveals New $76 Million Stake in Abbott Labs
Value investing firm Southeastern Asset Management, led by Mason Hawkins, initiated a new position in Abbott Laboratories during the second quarter of 2026....
Abbott Secures European Approval for Amulet 360, Reducing Stroke Risk
Abbott Laboratories secured CE Mark approval in Europe for its Amulet 360 Left Atrial Appendage (LAA) Occluder. The next-generation device prevents strokes in...
Abbott Wins FDA Approval for World's First Dual Glucose-Ketone Monitor
The FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable sensor to monitor glucose and ketone levels simultaneously. This biowearable is...
Lee Ainslie's Maverick Capital Exits $180M Stake in Abbott Laboratories
In a significant portfolio shift, Lee Ainslie's Maverick Capital fully liquidated its position in Abbott Laboratories during the second quarter of 2026. The...
Abbott Announces $670M Settlement for Preterm Infant Formula Litigation
Abbott Laboratories announced it has entered into agreements to pay approximately $670 million to resolve a portion of the litigation concerning its specialty...
Abbott settles $495 million verdict, resolving infant formula illness claims
Abbott Laboratories settled an appeal regarding a $495 million verdict involving its specialized formula for premature infants. A Missouri appeals court...